Skip to main content
Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.33
+0.29 (1.38%)
At close: Mar 9, 2026, 4:00 PM EDT
21.33
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:20 PM EDT

Immunome Revenue

In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.

Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
337.72
Revenue / Employee
$39,215
Employees
177
Market Cap
2.41B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20256.94M-2.10M-23.23%
Dec 31, 20249.04M-4.98M-35.50%
Dec 31, 202314.02M--
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Apellis Pharmaceuticals 1.00B
Telix Pharmaceuticals 803.79M
Travere Therapeutics 490.73M
Zai Lab 460.16M
Adaptive Biotechnologies 276.98M
Day One Biopharmaceuticals 158.18M
Tango Therapeutics 62.38M
Ocular Therapeutix 51.95M
Revenue Rankings

IMNM News

More News